Management, clinical Outcomes, and Its Predictors among Heart Failure Patients Admitted to Tertiary Care Hospitals in Ethiopia: Prospective Observational Study

doi:10.21203/rs.3.rs-2006837/v1

Download PDF

Research Article

Management, clinical Outcomes, and Its Predictors among Heart Failure Patients Admitted to Tertiary Care Hospitals in Ethiopia: Prospective Observational Study

https://doi.org/10.21203/rs.3.rs-2006837/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 06 Jan, 2023

Read the published version in BMC Cardiovascular Disorders →

You are reading this latest preprint version

Background

Heart failure is a global pandemic, as it affects approximately 64.34 million people worldwide with a $346.17 billion global economic burden. The prevalence of heart failure has increased from 43.4–46.5% in the last 10 years in lower and middle-income countries. This study aimed to assess management, clinical outcomes and their predictors among heart failure patients admitted to tertiary care hospitals in Ethiopia.

Methods

A prospective observational study design was conducted on heart failure patients admitted at two tertiary care hospitals in Ethiopia from September 2020 to May 2021. The primary outcome of the study was 90-day all-cause mortality. Data were analyzed using SPSS version 23.0. A multivariate Cox regression model was performed to identify independent predictors of 90-day all-cause mortality. Variables with P-values < 0.05 were considered statistically significant.

Results

Out of 283 patients enrolled in this study, 52.3% were male and the mean (± SD) age was 52.4 ± 17.9 years. The most common medications prescribed during hospitalization and discharge were diuretics (98.9% vs 95.6%), ACEIs/ARBs (48.8% vs 67.3%), and beta-blockers (46.6% vs 64.7%), respectively. In the present study, the 90-day all-cause mortality was 10.2%. Hypertension (HR = 3.70, 95%CI = 1.18–11.61), cardiogenic shock (HR = 8.66, 95%CI = 3.15–20.82), and reduced ejection fraction (HR = 1.47, 95%CI = 1.06–3.79) were predictors of 90-day all-cause mortality.

Conclusion

High 90-day all-cause mortality was observed among heart failure patients in the present study. Alcohol drinking, hypertension, cardiogenic shock, and reduced ejection fraction were predictors of poor treatment outcomes for whom closer follow-up or further interventions may be considered.

Heart failure

all-cause mortality

outcomes

Ethiopia

Heart failure (HF) is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. (1).

Population-based studies on the incidence and prevalence of HF in developing countries estimated that cardiovascular diseases (CVD) accounted for 7–10% of all medical admissions to African hospitals and HF constitutes 3–7% of these admissions (2). The prevalence cases of CVD in Ethiopia have increased approximately from 1.4 million in 1990 to 2.84 million in 2017. The disability-adjusted life years (DALYs) and mortality rates were 3,549.6 and 182.63, respectively in 2017 (3).

Heart failure is a global pandemic of cardiovascular disease, as it affects approximately 64.34 million people worldwide of who 29.5 million were males and 34.8 million were females, accounting for 9.91 million years lost due to disability. More specifically, the burden of HF has increased by 3.1% in the last 10 years in low-to-middle income countries (from 43.4–46.5% of all worldwide HF cases) (4) and it covers around 44% in Sub-Saharan Africa (5). Heart failure is responsible for significant health and economic burden. The global economic burden of HF is estimated at 346.17 billion US dollars with 5,380 US dollars per HF case as per the American heart association estimation (4).

Many comorbid conditions are associated with an increased propensity for structural heart disease. Hypertensive men and women have a substantially greater risk of developing HF than normotensive men and women. As well, the presence of clinical diabetic Mellitus markedly increases the likelihood of developing HF in patients without structural heart disease, obesity, or insulin resistance as well as increased development of HF (1, 6). The observational data supports the risk of smoking with increased heart failure mortality and rates of hospital admissions due to worsening heart failure compared with never, recent ex- and longer ex-smokers (7).

Among all causes of HF worldwide in 2017, ischemic heart disease accounted for the highest proportion (26.5%), followed by hypertensive heart disease (26.2%), chronic obstructive pulmonary disease (23.4%), another cardiomyopathy (6.5%), non-rheumatic degenerative mitral valve disease (2.7%), other cardiovascular and circulatory diseases (2.4%), alcoholic cardiomyopathy (2.4%), non-rheumatic calcific aortic valve disease (2.3%), rheumatic heart disease (1.8%), and myocarditis (1.7%) (8). A recent meta-analysis of studies in sub-Saharan Africa showed that hypertensive heart disease (39%) was the commonest cause of HF in sub-Saharan Africa, followed by cardiomyopathy (21%) and rheumatic heart disease (14%), with ischemic heart disease less frequent (7%) (9).

In the management of HF patients, angiotensin-converting enzyme inhibitors (ACEIs) have been shown to reduce mortality and morbidity in patients with HFrEF. Spironolactone or eplerenone are recommended in all symptomatic patients with HFrEF and ejection fraction ≤ 35%, to reduce mortality and HF hospitalization. In addition, diuretics are recommended to reduce the signs and symptoms of congestion in patients with HFrEF, but their effects on mortality and morbidity have not been studied in randomized controlled trials. Unfortunately, there are no treatment strategies with proven benefits to reduce mortality in patients with HFpEF, but calcium channel blockers and diuretics are used commonly (10–13).

The global study conducted by the international congestive heart failure study (INTER-CHF) among HF patients from low and middle-income countries reported that participants from Southeast Asia had an intermediate rate of mortality at the mean age of 57 years (15%) compared with patients in China, South America, and the Middle East patients who had the lowest rates of death at the mean age of 60 years, 69 years, and 72 years (7.3%, 9.1%, and 9.4%), respectively. However, Patients in India and Africa had the highest mortality at the mean age of 59 years and 56 years (23.3% and 33.6%), respectively (14).

In contrast to developed countries, there are limited studies: most of the studies are retrospective, conducted in a single setting, and a scanty number of participants were recruited on the treatment outcome of HF patients in sub-Saharan African countries, including Ethiopia. Hence, this study aimed to evaluate management, clinical outcomes, and their predictors among HF patients who were admitted to two tertiary care hospitals in Ethiopia.

Study design and clinical setting

A prospective observational study was conducted at two tertiary hospitals in Ethiopia including Jimma University Medical Center (JUMC) and Ambo University Referral Hospital (AURH). JUMC serves as a referral center for the southwestern part of the country (over 15,000,000 catchment population). JUMC provides general internal medicine, cardiology, and other clinical and diagnostic specialty services. AURH provides service through its medical units similar to JUMC for approximately 64,000 patients each year coming from different areas. The study was conducted from September 14, 2020, to May 30, 2021.

Study population

All consecutive HF patients admitted to JUMC and AURH fulfilling the inclusion criteria were included. Patients were included if they fulfilled the following inclusion criteria: (I) age ≥ 18 years; (II) both newly diagnosed and known HF patients; and (III) both clinically and echocardiograph confirmed diagnosis (the suspected heart failure based on signs and symptoms of HF with or without abnormal electrocardiogram (ECG) is settled by echocardiography (10)) of HF patients. Patients who are unwilling to participate in this study and patients with isolated right-sided heart failure (Cor-pulmonale) were excluded from the study.

Data collection

Using a pre-tested structured questionnaire, two trained nurses and two pharmacists collected clinical data by interviewing hospitalized patients and extracting relevant data from patients' medical records. The data collection tool includes socio-demographic characteristics, key diagnostics investigations (cardiac troponin, complete blood count, electrocardiography, and echocardiography), medication profiles, and clinical outcomes.

Study outcomes and validating tools

The primary outcome of the study was 90-day all-cause mortality which was ascertained from the treating physician's death summary note and/or contacting the patient's family via telephone. All clinical endpoints were recorded by following patients on daily basis from admission to discharge or death.

Statistical analysis

The collected data were checked for completeness, consistency, clarity, and accuracy. Data was entered into Epidata version 3.1 and analyzed using the statistical package for social science (SPSS) version 23. Continuous variables were presented as mean (±SD) for normally distributed variables, and/or median (inter-quartile range) for non-normal distributed variables, and categorical variables are presented as frequency (%). 90-day all-cause HF mortality rate was compared using Kaplan-Meier and log-rank test. P-value < 0.25 was considered as a cut-off point to select variables on univariate regression for multivariable Cox regression to determine independent predictors of 90-day all-cause mortality. Two-tailed p-value < 0.05 was considered statistically significant.

Socio-demographic characteristics and behavioral measures

Among 283 HF patients enrolled in the study, 52.3% were male and the mean (± standard deviation) age was 52.4 ± 17.9 years old. Of these, 189 (66.8%) participants were younger than 65 years old, 180 (63.6%) were rural residents, 141 (49.8%) had no formal education, 98 (34.6%) were farmer/labor workers, 192 (67.8%) were non-adherent to salt intake recommendations, and 67 (23.7%) were alcohol drinkers (see Table 1).

Comorbid conditions

Among 283 participants, 206 (72.8%) had documented comorbid conditions. Of these, the most common comorbid conditions in order of decreasing frequency were hypertension 107 (51.9%), diabetic Mellitus 25 (12.1%), and liver disease 22 (10.7%) (see Fig. 1).

Table 1

Baseline socio-demographic characteristics and behavioral measures of heart failure patients admitted to JUMC and AURH, Ethiopia between September 01, 2020, to March 01, 2021
Demographics	Categories	Frequency (%)
Age (in years)	Mean (± SD)	52.4 ± 17.9
	< 25	23 (8.1)
	25–54	109 (38.5)
	55–64	57 (20.1)
	≥ 65	94 (33.2)
Gender	Female	135 (47.7)
Gender	Male	148 (52.3)
Residence	Rural	180 (63.6)
Residence	Urban	103 (36.4)
Marital status	Single	31 (11.0)
Marital status	Married	252 (89.0)
Education level	No formal education	141 (49.8)
	Primary school	30 (10.6)
	Secondary school	47 (16.6)
	Tertiary education	65 (23.0)
Occupational status	Unemployed/retired	83 (29.3)
	Farmer/labor worker	98 (34.6)
	Housewife	54 (19.1)
	Employed (Govt/NGO)	48 (17.0)
Non-adherent to low salt intake	Yes	192 (67.8)
Cigarette smoking	Yes	36 (12.7)
Khat chewing	Yes	80 (28.3)
Alcohol drinking habits	Yes	67 (23.7)
SD-Standard deviation, Govt/NGO-Government or Non-government organization

Clinical characteristics

Among 283 patients included in the current study, 72 (25.4%) and 110 (38.9%) had elevated systolic and diastolic blood pressure, respectively. Two hundred seventy (95.4%) participants had structural heart disease at stage C and 226 (79.9%) patients were functional class IV HF. The leading causes of HF on echocardiography findings were, ischemic heart disease 133 (47.0%) of the patients followed by hypertensive heart disease101 (35.7%), dilated cardiomyopathy 60 (21.2%), and chronic rheumatoid valvular heart disease 50 (17.7%) (see Fig. 2). The three most common precipitating factors of HF in the descending order of frequency were community-acquired pneumonia 122 (57.8%), atrial fibrillation 60 (28.4%), and drug discontinuation 49 (23.2%) ( see Table 2). The reason for drug discontinuation was COVID-19 negative impact 26 (53.1%).

Laboratory and imaging investigations

Among 283 HF patients assessed in this study, 208 (73.5%) had a recorded echocardiographic finding with the results of 100 (48.1%) HFrEF, 76 (36.5%) HFpEF, and 32 (15.4%) had a mid-range ejection fraction (Fig. 3). Of these, there were 138 (59.2%) abnormal ECG, 69 (27.4%) elevated serum creatinine, and 77 (43.0%) hyponatremia. There was 136 (50.9%) low hemoglobin level record, of these 36 (12.7%) were diagnosed with significant anemia (see Table 3).

Table 2: Clinical characteristics of heart failure patients admitted to JUMC and AURH, Ethiopia between September 01, 2020, to March 01, 2021

Parameters

Frequency (%)

Systolic BP ≥130 mmHg

72 (25.4)

Diastolic BP ≥80 mmHg

110 (38.9)

Heart rate (bpm) (n=239)

<60

≥100

12 (5.0)

124 (51.9)

Patient type

Newly diagnosed HF

Known HF

127 (44.9)

156 (55.1)

Duration of HF (in years) (n=156)

≤5

120 (76.9)

36 (23.1)

Stage of HF

3 (1.1)

270 (95.4)

10 (3.5)

NYHA class

III

4 (1.4)

53 (18.7)

226(79.9)

Precipitating factor of HF (n=211)

Community-acquired pneumonia

Atrial fibrillation

Drug discontinuation

Acute coronary syndrome

Pulmonary tuberculosis

Others*

122 (57.8)

60 (28.4)

49 (23.2)

17 (8.0)

64 (30.3)

*Exacerbated chronic obstructive pulmonary disease and asthma, severe pulmonary hypertension, left ventricular thrombus, thyroid disorder

Table 3: Laboratory and imaging investigations values of heart failure patients admitted to JUMC and AURH, Ethiopia between September 01, 2020, to March 01, 2021

Parameters	Frequency (%)
Electrocardiogram (n=233)
Normal Abnormal	95 (40.8) 138 (59.2)
Troponin (n=67) ≥1.5 ng/L	28 (41.8)
Serum creatinine (n=252) >1.2 mg/Dl	69 (27.4)
Thyroid-stimulating hormone (µU/mL) (n=26) <0.5 >4.7	11 (42.4) 1 (3.8)
Liver function test (IU/L) (n=206) AST>40 ALT>40	72 (35.0) 57 (27.7)
Sodium (n=179) <135 mEq/L	77 (43.0)
Potassium (mEq/L) (n=179) <3.5 >5.5 Complete blood count (n=267)	37 (20.7) 11 (6.1)
Leukocytosis (WBC> 12000 cell/mm³ )	38 (14.2)
Low hemoglobin (mg/dL)*	136 (50.9)
a= Sinus tachycardia, atrial fibrillation, atrial flutter, sinus bradycardia, ST elevation/depression * <13 for males and <12 for females as per world health organization (WHO) criteria (15)

Management

Of a total of 283 patients enrolled in the current study, 170 (60.1%) had past medication history, 283 (100.0%) had in-hospital current medications records, and 251 (88.7%) had documented discharge medications. During hospitalization, diuretics (98.9%) were used as the predominant class of drugs. It is also used most commonly than other classes of drugs during both pre-hospitalization and post-hospitalization. ACEIs/ARBs 169 (67.3%) and beta-blockers 162 (64.5%) were commonly used during post-hospitalization. During hospitalization, 188 (66.4%) patients were prescribed antibiotics, among these, 145 (77.1%) were diagnosed as significantly infectious (see Table 4).

Outcomes

In-hospital events

Arrhythmia 69 (24.4%) was the most common cause of in-hospital complications of HF, followed by acute kidney injury 38 (13.4%) and cardiogenic shock 20 (7.1%). The median length of hospital stay was 14 (IQR = 9, 19) days with 25 (8.8%) in-hospital deaths (see Table 5).

Predictors of 90-day all-cause mortality

The Kaplan Meier survival curves (see Fig. 4) show there was a significant difference in the survival status of patients with HFrEF, HF with mid-range EF, and HFpEF (Log Rank test, P = 0.024). The variables that showed significant association (p-value < 0.25) on univariate Cox regression analysis were alcohol consumption, atrial fibrillation, cardiogenic shock, anemia, and reduced ejection fraction which were significantly associated with 90-day all-cause mortality. On other hand, the variables that were identified by multivariate Cox regression analysis were the presence of hypertension, alcohol drinking, cardiogenic shock, reduced ejection fraction, and absence of ACEIs/ARBs, which significantly predicted 90-day all-cause mortality (see Table 6).

The 90-day all-cause mortality in HF patients hospitalized in two Ethiopian tertiary hospitals was observed in this study. Ischemic heart disease (47%) and hypertension (51.9%) were the most frequent underlying and co-morbid diseases, respectively. Among HF patients assessed in the current study, 57.8% were precipitated by pneumonia. The 90-day all-cause mortality of this study was 10.2%.

Among 283 patients assessed, 66.8% were younger than 65 years old, with a mean (± SD) age of 52.4 ± 17.9 years. When we compare the demographic characteristics of patients with heart failure revealed by this study to data from studies conducted in the USA, almost 75% of HF patients were > 65 years, with a mean (± SD) age of 69.1 ± 13.5 years, and in Spain, 66.7% of HF patients were > 65 years, with a mean (± SD) age of 72.8 ± 11.2 years (16, 17). Living styles, socioeconomic status of patients, and environmental, and genetic factors were believed to be the possible causes of these disparities. Tromp J, et al. (18) (ASIAN-HF) conducted a study in 11 Asian regions that showed that more than 50% of HF patients were < 65 years old. On the other hand, Abebe et al.(19) and Tirfe et al.(20) reported comparable findings in Ethiopia more than 66% of participants were < 65 years old.

Approximately 80% of the HF patients in this study had NYHA class IV. A study conducted in Spain by Farré N, et al.(21) and in Japan by T. Shiga, et al.(22) showed that 75% and 36.1% of patients had NYHA class III-IV respectively, which is relatively different from the current study. On the other hand, Woldeyes E, et al.(23) conducted a study in Ethiopia and showed that 90.3% of NYHA class IV patients, which is relatively consistent with the current study. This demonstrates that HF patients in Ethiopia come with later-stage symptoms when they visit a health facility. The socio-economic status of the patients, distance from the hospital, low level of awareness about the disease, and the quality of health care services might be all likely factors in these late-stage presentations.

Table 4

Management (past, in-hospital, and discharge medications) of heart failure patients admitted to JUMC and AURH, Ethiopia between September 01, 2020, to March 01, 2021
Medications	Frequency (%)
Medications	Past medication history In-hospital medications Discharge medications (n = 170) (n = 283) ( n = 251)
ACEIs/ARBs	99 (58.2)	138 (48.8)	169 (67.3)
Diuretics	147 (86.5)	280 (98.9)	240 (95.6)
Beta-blockers*	77 (45.3)	132 (46.6)	162 (64.5)
CCBs	15 (8.8)	30 (10.6)	30 (12.0)
MRAs	21 (12.4)	46 (16.3)	27 (10.8)
Cardiac glycoside	16 (9.4)	32 (11.3)	31 (12.4)
Statins	57 (33.5)	126 (44.5)	120 (47.8)
Anticoagulant	18 (10.6)	71 (25.1)	4 (1.6)
Antiplatelet	47 (27.6)	125 (44.2)	98 (44.6)
Antibiotics	-	188 (66.4)	-
ACEIs/ARBs-angiotensin converting enzyme inhibitors or angiotensin receptor blockers, CCBs-calcium channel blockers, MRAs-mineralocorticoid receptor antagonists * Metoprolol and carvedilol

Table 5

In-hospital events (complications, length of stay, mortality) of heart failure patients admitted to JUMC and AURH, Ethiopia between September 01, 2020, to March 01, 2021
Events	Frequency (%)
In-hospital complication HF (n = 135)
Arrhythmia Acute kidney injury Cardiogenic shock Acute ischemia Hospital-acquired infection	69 (24.4) 38 (13.4) 20 (7.1) 17 (6.0) 7 (2.5)
In-hospital mortality	25 (8.8)
Hospital stay, median (interquartile range)	14 (IQR = 9, 19) days

Hypertension was shown to be the most common risk factor for HF in this study (51.9%). According to a study conducted in the USA (75.6%), New Zealand and Singapore (67.8%), Tanzania (41%), and South Africa (46%), hypertension was the most common risk factor for HF patients (16, 24–26). In this study, the possible causes of the high proportion of hypertension as a risk factor for HF were a lack of adherence to salt intake recommendations, inadequate quality of health care services, the poor lifestyle of the patients, poor diet monitoring habits, race variation, environmental, and genetic factors. On the other hand, when compared to the findings of a previous study conducted in Ethiopia by Abebe et al.(19) and Abdissa et al.(27), the most common risk factor for heart failure was valvular heart disease, followed by hypertensive heart disease, coronary heart disease, and ischemic heart disease, which is not in line with the current study.

The most common precipitating variable in the current study was pneumonia (57.8%), followed by atrial fibrillation, drug discontinuation, and acute coronary syndrome. In Ethiopia, a study conducted by Zeru MA (28) revealed that pneumonia (42%) was the most common cause of HF exacerbation, followed by arrhythmia, anemia, myocardial infarction, and drug discontinuation. Lack of adult pneumococcal and influenza vaccination for patients with chronic disease and home surrounding hygiene of the patients might be the likely causes of HF exacerbation by pneumonia.

In the current study, diuretics were the most commonly prescribed drug for HF patients, followed by ACEIs/ARBs, beta-blockers, statins, antiplatelet, mineralocorticoid receptor antagonists, digoxin, and calcium channel blockers. Abebe et al. (19) conducted a similar study in Ethiopia showing that diuretics were used most commonly, followed by beta-blockers, ACEIs/ARBs, mineralocorticoid receptor antagonists, digoxin, and statins. Another study from Japan, New Zealand and Singapore showed that diuretics were used most commonly, followed by beta-blockers, ACEIs/ARBs, mineralocorticoid receptor antagonists, and statins for HF patients (22, 24). On the other hand, findings from studies in the USA and Spain revealed that HF patients were treated with ACEIs/ARBs most commonly, followed by beta-blockers, diuretics, digoxin, and statins, which is relatively not consistent with our study (16, 20). The increased consumption of diuretics in Ethiopia was possible due to the presentation of HF patients with congestion as a result of non-adherence to salt intake recommendations and the drugs' easy availability.

This finding revealed a 90-day all-cause mortality rate of 10.2%, which is relatively similar to a study conducted in the USA by Sarijaloo et al.(29) the 90-day follow-up showed an 11.5% of all-cause mortality rate. The slight discrepancies in these studies were due to the number of participants enrolled, ethnic variation, and genetic factors. Another study that is not in line with the current study was reported by Tirfe et al.(20) in Ethiopia, with in-hospital mortality (17.2%) with 4 months of prospective observational study and a report from Japan by T. Shiga, et al.(22) (17%) with 19 months of follow-up. Specifically, all-cause mortality of the present study was lower than T. Shiga, et al.’s findings, which might be the most likely causes of differences in follow-up period length, study design, number of study participants enrolled, environmental, and genetic factors.

Table 6

A 90-day all-cause mortality independent predictors of heart failure patients admitted to JUMC and AURH, Ethiopia between September 01, 2020, to March 01, 2021
Univariate analysis				Multivariate analysis
Variables	Description	HR (95% CI)	P-value	HR (95% CI)	P-value
Alcohol drinking	Yes	1.72 (0.80–3.69)	0.167	2.83 (1.03–7.75)	0.043
Hypertension	Yes	1.55 (0.74–3.22)	0.243	3.70 (1.18–11.61)	0.025
CRVHD	Yes	1.75 (0.71–4.29)	0.223	1.85 (0.46–7.39)	0.387
Atrial fibrillation	Yes	4.33 (1.51–12.46)	0.007	2.12 (0.64–6.98)	0.218
Anemia	Yes	1.88 (0.77–4.63)	0.167	2.72 (0.75–9.91)	0.130
CAP	Yes	1.66 (0.80–3.46)	0.173	1.46 (0.48–4.46)	0.512
Cardiogenic shock	Yes	8.81(4.08–18.90)	< 0.001	8.66 (3.15–20.82)	< 0.001
Rehospitalization	Yes	1.73 (0.81–3.73)	0.159	1.25 (0.42–3.73)	0.684
Ejection fraction (%)	≤ 40%	1.02 (0.99–1.05)	0.196	1.47 (1.06–3.79)	0.014
ACEIs/ARBs	Yes	0.55 (0.25–1.18)	0.122	0.02 (0.003–0.16)	< 0.001
ACEIs/ARBs-angiotensin converting enzyme inhibitors/angiotensin receptor blockers, CAP-community acquired pneumonia, CI-confidence interval, CRVHD-chronic valvular heart disease, HR-hazard ratio

In the current study, multivariate Cox regression analysis showed that the independent predictors of 90-day all-cause mortality in HF patients were alcohol drinking, presence of hypertension, reduced ejection fraction, cardiogenic shock, and absence of ACEIs/ARBs medications. In a comparable study report from the international registry (REPORT-HF) by Tromp J, et al.(30) across all regions, the common predictors of worse 1-year mortality were lower systolic blood pressure and not receiving ACEIs or β blockers at discharge. A similar study done in Israel by Segal et al.(31) exhibited that the predictors of all-cause mortality were admission systolic blood pressure ≥ 140 mmHg. Another study conducted in Zambia by Chansa P, et al.(32) showed that the predictors of all-cause mortality were left ventricular ejection fraction < 40%.

Strength and limitations of the study

The lack of laboratory value on brain natriuretic peptide, which is sensitive to HF diagnosis, was one of the study's limitations. Furthermore, heart investigations and laboratory results such as an echocardiogram, electrocardiogram, cardiac troponin, serum electrolyte, and liver function tests were not obtained fully. The cause of death after discharge could not be determined in detail. Despite these limitations, our study provides vital information on the clinical characteristics, management, and prognosis of HF patients.

High 90-day all-cause mortality was observed among heart failure patients in the present study. The most common co-morbid diseases and etiology in patients admitted with HF were hypertension and ischemic heart disease. Furthermore, pneumonia was the principal precipitating factor of HF. Alcohol drinking, presence of hypertension, reduced ejection fraction, cardiogenic shock, and the absence of ACEIs/ARBs medications were all predictors of poor treatment outcomes for whom closer monitoring or further interventions may be considered.

AURH

Ambo university referral hospital

ACEI

Angiotensin Converting Enzyme Inhibitors

ARB

Angiotensin Receptor Blockers

CVD

Cardiovascular Diseases

JUMC

Jimma University Medical Center

Heart failure

HFpEF

Heart failure with a preserved ejection fraction

HFrEF

Heart failure with a reduced ejection fraction

Acknowledgements

We would like to acknowledge Jimma University collaborated with Adama hospital medical college for funding this study. We are also grateful to all the study participants who gave their consent to participate in this study.

Funding

This research was financially supported by Jimma University Institute of Health Science collaborated with Adama hospital medical college. The funding body did not have any role in study design, data collection, data analysis, interpretation of data, or writing the manuscript.

Availability of data and materials

The data set that was used to support the finding of this study will be made available from the corresponding author upon reasonable request.

Consent for publications

Not applicable

Ethical approval and consent to participate

The study protocol was approved by the Institutional Review Board (IRB) of Jimma University, Institute of Health with a reference number of IRB/000195/01/04/2020. The research was conducted in accordance with the Declaration of Helsinki recommendations (33). Permission was obtained from responsible bodies of respective hospitals before interviewing patients and extracting data from active patients' case records. Written and verbal informed consent was obtained from all study participants. The confidentiality, autonomy, and beneficence of the patients were kept throughout the study period and only the principal investigator, supervisors, and data collectors had access to the patient's information.

Competing interests

The authors declare that there is no competing of interest regarding this work.

Authors Contributions

Birhanu Beri and Korinan Fanta had involved in the design, implementation of the study, performed the statistical analysis, and drafted the manuscript. Fekede Bekele and Worku Bedada conceived and designed the study, were involved in the implementation of the study, performed the statistical analysis, and critically revised the manuscript. All the authors read and approved the final manuscript.

Author’s information

¹Jimma university, institute of health sciences, School of Pharmacy, Clinical Pharmacy Course and Research Team, P.O.Box: 378, Jimma, Oromia, Ethiopia

²Former Dean and Research Director of Salale University P.O.Box: 378, Jimma, Oromia, Ethiopia

Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, et al. 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). American College of Cardiology. 2021;77(16):2053-150.
Adebayo SO, Olunuga TO, Durodola A, Ogah OS. Heart failure: Definition, classification, and pathophysiology–A mini-review. Nigerian Journal of Cardiology. 2017;14(1):9.
Ali S, Misganaw A, Worku A, Destaw Z, Negash L, Bekele A, et al. The burden of cardiovascular diseases in Ethiopia from 1990 to 2017: evidence from the Global Burden of Disease Study. J International Health. 2020;0:1-9.
Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.
Seid MA, Abdela OA, Zeleke EG. Adherence to self-care recommendations and associated factors among adult heart failure patients. From the patients’ point of view. J PloS one. 2019;14(2):e0211768.
van der Meer P, Gaggin HK, Dec GW. ACC/AHA versus ESC guidelines on heart failure: JACC guideline comparison. Journal of the American College of Cardiology. 2019;73(21):2756-68.
Network SIG. Management of chronic heart failure: a national clinical guideline: Scottish Intercollegiate Guidelines Network; 2016.
Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. European Journal of Preventive Cardiology. 2021;4(2):178-89.
Yuyun MF, Sliwa K, Kengne AP, Mocumbi AO, Bukhman G. Cardiovascular diseases in Sub-Saharan Africa compared to high-income countries: an epidemiological perspective. Global Heart. 2020;15(1):15.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2016;18(8):891-975.
McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Canadian Journal of Cardiology. 2021;37(4):531-46.
Mishra S, Mohan J, Nair T, Chopra V, Harikrishnan S, Guha S, et al. Management protocols for chronic heart failure in India. Indian heart journal. 2018;70(1):105-27.
AlHabeeb W, Al-Ayoubi F, AIGhalayini K, Al Ghofaili F, Al Hebaishi Y, Al-Jazairi A, et al. Saudi Heart Association (SHA) guidelines for the management of heart failure. Journal of the Saudi Heart Association. 2019;5:324-54.
Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet Global Health. 2017;5(7):e665-e72.
Organization WH. Hemoglobin concentrations for the diagnosis of anemia and assessment of severity. World Health Organization; 2011.
Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, et al. Heart failure with mid‐range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC heart failure. 2019;6(4):784-92.
Santas E, Valero E, Mollar A, García-Blas S, Palau P, Miñana G, et al. Burden of recurrent hospitalizations following an admission for acute heart failure: preserved versus reduced ejection fraction. Revista Española de Cardiología. 2017;70(4):239-46.
Tromp J, Tay WT, Ouwerkerk W, Teng T-HK, Yap J, MacDonald MR, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS medicine. 2018;15(3):e1002541.
Abebe TB, Gebreyohannes EA, Tefera YG, Abegaz TM. Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study. BMC cardiovascular disorders. 2016;16(1):232.
Tirfe M, Nedi T, Mekonnen D, Berha AB. Treatment outcome and its predictors among patients of acute heart failure at a tertiary care hospital in Ethiopia: a prospective observational study. BMC cardiovascular disorders. 2020;20(1):1-10.
Farré N, Lupon J, Roig E, Gonzalez-Costello J, Vila J, Perez S, et al. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). BMJ open. 2017;7(12):e018719.
Shiga T, Suzuki A, Haruta S, Mori F, Ota Y, Yagi M, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid‐range, and reduced ejection fractions in Japan. ESC heart failure. 2019;6(3):475-86.
Woldeyes E ZH, Hailu A, Bayissa T, Sirgu S. . Five years Clinical characteristics and in-hospital outcome of acute heart failure at tertiary care hospital in Ethiopia. Ethiopian Medical Journal. 2020;58(01):43–51.
Lam CS, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. European heart journal. 2018;39(20):1770-80.
Raphael DM, Roos L, Myovela V, Mchomvu E, Namamba J, Kilindimo S, et al. Heart diseases and echocardiography in rural Tanzania: Occurrence, characteristics, and etiologies of underappreciated cardiac pathologies. PloS one. 2018;13(12).
Kraus S, Ogunbanjo G, Sliwa K, Ntusi NA. Heart failure in sub-Saharan Africa: A clinical approach. SAMJ: South African Medical Journal. 2016;106(1):23-31.
Abdissa SG, Oli K, Feleke Y, Goshu DY, Begna DM, Tafese A. Spectrum of cardiovascular diseases among Ethiopian patients at Tikur Anbessa Specialized University Teaching Hospital, Addis Ababa. Ethiop Med J. 2014;52(1):9-17.
Zeru MA. Assessment of major causes of heart failure and its pharmacologic management among patients at Felege Hiwot referral hospital in Bahir Dar, Ethiopia. Journal of Public Health and Epidemiology. 2018;10(9):326-31.
Sarijaloo F, Park J, Zhong X, Wokhlu A. Predicting 90-day acute heart failure readmission and death using machine learning‐supported decision analysis. Clinical cardiology. 2021;44(2):230-7.
Tromp J, Bamadhaj S, Cleland JG, Angermann CE, Dahlstrom U, Ouwerkerk W, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. The Lancet Global Health. 2020;8(3):e411-e22.
Segal O, Segal G, Leibowitz A, Goldenberg I, Grossman E, Klempfner R. Elevation in systolic blood pressure during heart failure hospitalization is associated with increased short and long-term mortality. J Medicine. 2017;96(5):12-6.
Chansa P, Lakhi S, Andrews B, Kalinchenko S, Sakr R. Factors associated with mortality in adults admitted with heart failure at the University Teaching Hospital in Lusaka, Zambia. Medical Journal of Zambia. 2014;41(1):4-12.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053. PMID: 24141714.

No competing interests reported.

Download PDF

Journal Publication

published 06 Jan, 2023

Read the published version in BMC Cardiovascular Disorders →

Editorial decision: Major revision
11 Oct, 2022
Reviews received at journal
05 Oct, 2022
Reviewers agreed at journal
28 Sep, 2022
Reviewers agreed at journal
28 Sep, 2022
Reviewers invited by journal
28 Sep, 2022
Editor assigned by journal
28 Sep, 2022
Editor invited by journal
06 Sep, 2022
Submission checks completed at journal
06 Sep, 2022
First submitted to journal
28 Aug, 2022

You are reading this latest preprint version

Management, clinical Outcomes, and Its Predictors among Heart Failure Patients Admitted to Tertiary Care Hospitals in Ethiopia: Prospective Observational Study

Status:

Journal Publication

Version 1

Abstract

Background

Methods

Results

Conclusion

Figures

Introduction

Methods And Participants

Results

Socio-demographic characteristics and behavioral measures

Comorbid conditions

Clinical characteristics

Laboratory and imaging investigations

Management

Outcomes

In-hospital events

Predictors of 90-day all-cause mortality

Discussion

Strength and limitations of the study

Conclusion

Abbreviations

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 1